GLP-1RAs and Dual GIP/GLP-1 Agonists Consistently Lower CRP, MDA, and Increase Adiponectin in Type 2 Diabetes
Background
Despite GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists demonstrating improved cardiovascular outcomes in Type 2 Diabetes Mellitus (T2DM), their precise impact on inflammatory and oxidative stress biomarkers remains incompletely understood. Current standard-of-care for T2DM primarily targets glycemic control, but the broader metabolic and anti-inflammatory benefits of incretin-based therapies are a critical area of investigation. Understanding these effects could refine treatment strategies and improve long-term patient outcomes beyond glucose management.
Study Design
This systematic review and meta-analysis included 41 randomized controlled trials (RCTs) in adults with T2DM. Researchers compared GLP-1RAs or dual GIP/GLP-1 agonists against placebo or active therapies. The primary endpoints were changes in inflammatory biomarkers like C-reactive protein (CRP/hs-CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and oxidative stress marker malondialdehyde (MDA), alongside the metabolic biomarker adiponectin. Data was extracted from PubMed, Ovid MEDLINE, Scopus, Web of Science, and Cochrane Library up to February 19, 2026, with random-effects meta-analyses using standardized mean differences (SMDs).
Results
In adults with T2DM, incretin-based therapies demonstrated significant and consistent effects on several key biomarkers. GLP-1RAs significantly reduced CRP/hs-CRP (27 studies, 1991 participants; SMD -0.37, 95% CI -0.59 to -0.14) and MDA (3 studies, 272 participants; SMD -0.98, 95% CI -1.65 to -0.30). They also significantly increased adiponectin (16 studies, 1327 participants; SMD 0.30, 95% CI 0.13 to 0.46). Pooled effects on IL-6 (17 studies, 1068 participants; SMD -0.14, 95% CI -0.37 to 0.10), TNF-α (16 studies, 1164 participants; SMD -0.25, 95% CI -0.61 to 0.12), and MCP-1 (7 studies, 450 participants; SMD -0.27, 95% CI -0.58 to 0.03) were not statistically significant, though MCP-1 decreased in sensitivity analyses.
Notably, two tirzepatide RCTs (562 participants) showed a significant reduction in IL-6 (
SMD -0.28, 95% CI -0.47 to -0.09), alongside a non-significant trend towards lower CRP/hs-CRP.
Key Findings
- GLP-1RAs significantly reduced CRP/hs-CRP by
SMD -0.37(95% CI -0.59 to -0.14) across 27 studies (1991 participants). - GLP-1RAs significantly decreased malondialdehyde (MDA) by
SMD -0.98(95% CI -1.65 to -0.30) in 3 studies (272 participants). - GLP-1RAs significantly increased adiponectin by
SMD 0.30(95% CI 0.13 to 0.46) across 16 studies (1327 participants). - Pooled effects on IL-6, TNF-α, and MCP-1 were not statistically significant for GLP-1RAs alone.
- Two tirzepatide RCTs showed a significant reduction in IL-6 by
SMD -0.28(95% CI -0.47 to -0.09).
Why It Matters
This meta-analysis provides strong evidence that GLP-1RAs and dual GIP/GLP-1 agonists offer benefits beyond glycemic control, exerting selective anti-inflammatory and metabolic regulatory effects. Clinicians can now consider these therapies not just for glucose management, but also for their potential to mitigate systemic inflammation and oxidative stress in T2DM patients. The consistent reduction in CRP and MDA, coupled with increased adiponectin, suggests a broader protective profile that could contribute to improved cardiovascular outcomes. While effects on IL-6 and TNF-α were variable for GLP-1RAs, the specific reduction in IL-6 by tirzepatide highlights the potential for dual agonists to offer more comprehensive anti-inflammatory actions. This supports the continued exploration of these peptides for their pleiotropic effects.
glp-1ra
gip-glp-1-agonist
tirzepatide
type-2-diabetes
inflammation
oxidative-stress